Blockade of the deubiquitinating enzyme USP48 degrades oncogenic HMGA2 and inhibits colorectal cancer invasion and metastasis

HMGA2, a pivotal transcription factor, functions as a versatile regulator implicated in the progression of diverse aggressive malignancies. In this study, mass spectrometry was employed to identify ubiquitin-specific proteases that potentially interact with HMGA2, and USP48 was identified as a deubi...

Full description

Bibliographic Details
Main Authors: Can Cheng, Hanhui Yao, Heng Li, Jingwen Liu, Zhengyi Liu, Yang Wu, Liang Zhu, Hejie Hu, Zhengdong Fang, Liang Wu
Format: Article
Language:English
Published: Elsevier 2024-04-01
Series:Acta Pharmaceutica Sinica B
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S221138352400008X
_version_ 1797248334487879680
author Can Cheng
Hanhui Yao
Heng Li
Jingwen Liu
Zhengyi Liu
Yang Wu
Liang Zhu
Hejie Hu
Zhengdong Fang
Liang Wu
author_facet Can Cheng
Hanhui Yao
Heng Li
Jingwen Liu
Zhengyi Liu
Yang Wu
Liang Zhu
Hejie Hu
Zhengdong Fang
Liang Wu
author_sort Can Cheng
collection DOAJ
description HMGA2, a pivotal transcription factor, functions as a versatile regulator implicated in the progression of diverse aggressive malignancies. In this study, mass spectrometry was employed to identify ubiquitin-specific proteases that potentially interact with HMGA2, and USP48 was identified as a deubiquitinating enzyme of HMGA2. The enforced expression of USP48 significantly increased HMGA2 protein levels by inhibiting its degradation, while the deprivation of USP48 promoted HMGA2 degradation, thereby suppressing tumor invasion and metastasis. We discovered that USP48 undergoes SUMOylation at lysine 258, which enhances its binding affinity to HMGA2. Through subsequent phenotypic screening of small molecules, we identified DUB-IN-2 as a remarkably potent pharmacological inhibitor of USP48. Interestingly, the small-molecule inhibitor targeting USP48 induces destabilization of HMGA2. Clinically, upregulation of USP48 or HMGA2 in cancerous tissues is indicative of poor prognosis for patients with colorectal cancer (CRC). Collectively, our study not only elucidates the regulatory mechanism of DUBs involved in HMGA2 stability and validates USP48 as a potential therapeutic target for CRC, but also identifies DUB-IN-2 as a potent inhibitor of USP48 and a promising candidate for CRC treatment.
first_indexed 2024-04-24T20:12:56Z
format Article
id doaj.art-42afa62e871648bdbf3a72b745f781e9
institution Directory Open Access Journal
issn 2211-3835
language English
last_indexed 2024-04-24T20:12:56Z
publishDate 2024-04-01
publisher Elsevier
record_format Article
series Acta Pharmaceutica Sinica B
spelling doaj.art-42afa62e871648bdbf3a72b745f781e92024-03-23T06:24:06ZengElsevierActa Pharmaceutica Sinica B2211-38352024-04-0114416241643Blockade of the deubiquitinating enzyme USP48 degrades oncogenic HMGA2 and inhibits colorectal cancer invasion and metastasisCan Cheng0Hanhui Yao1Heng Li2Jingwen Liu3Zhengyi Liu4Yang Wu5Liang Zhu6Hejie Hu7Zhengdong Fang8Liang Wu9Department of General Surgery, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, China; Anhui Province Key Laboratory of Hepatopancreatobiliary Surgery, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, ChinaDepartment of General Surgery, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, China; Anhui Province Key Laboratory of Hepatopancreatobiliary Surgery, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, ChinaAnhui Province Key Laboratory of Hepatopancreatobiliary Surgery, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, China; Department of Comprehensive Surgery, Anhui Provincial Cancer Hospital, West District of the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, ChinaAnhui Provincial Hospital Health Management Center, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, ChinaDepartment of Breast Surgery, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, People's Hospital of Henan University, Zhengzhou 450003, ChinaDepartment of General Surgery, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, China; Anhui Province Key Laboratory of Hepatopancreatobiliary Surgery, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, ChinaDepartment of General Surgery, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, ChinaDepartment of General Surgery, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, China; Corresponding authors.Department of General Surgery, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, China; Corresponding authors.Department of General Surgery, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, China; Anhui Province Key Laboratory of Hepatopancreatobiliary Surgery, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, China; Corresponding authors.HMGA2, a pivotal transcription factor, functions as a versatile regulator implicated in the progression of diverse aggressive malignancies. In this study, mass spectrometry was employed to identify ubiquitin-specific proteases that potentially interact with HMGA2, and USP48 was identified as a deubiquitinating enzyme of HMGA2. The enforced expression of USP48 significantly increased HMGA2 protein levels by inhibiting its degradation, while the deprivation of USP48 promoted HMGA2 degradation, thereby suppressing tumor invasion and metastasis. We discovered that USP48 undergoes SUMOylation at lysine 258, which enhances its binding affinity to HMGA2. Through subsequent phenotypic screening of small molecules, we identified DUB-IN-2 as a remarkably potent pharmacological inhibitor of USP48. Interestingly, the small-molecule inhibitor targeting USP48 induces destabilization of HMGA2. Clinically, upregulation of USP48 or HMGA2 in cancerous tissues is indicative of poor prognosis for patients with colorectal cancer (CRC). Collectively, our study not only elucidates the regulatory mechanism of DUBs involved in HMGA2 stability and validates USP48 as a potential therapeutic target for CRC, but also identifies DUB-IN-2 as a potent inhibitor of USP48 and a promising candidate for CRC treatment.http://www.sciencedirect.com/science/article/pii/S221138352400008XColorectal cancerInvasion and metastasisPost-translational modificationUbiquitinationSUMOylationUSP48
spellingShingle Can Cheng
Hanhui Yao
Heng Li
Jingwen Liu
Zhengyi Liu
Yang Wu
Liang Zhu
Hejie Hu
Zhengdong Fang
Liang Wu
Blockade of the deubiquitinating enzyme USP48 degrades oncogenic HMGA2 and inhibits colorectal cancer invasion and metastasis
Acta Pharmaceutica Sinica B
Colorectal cancer
Invasion and metastasis
Post-translational modification
Ubiquitination
SUMOylation
USP48
title Blockade of the deubiquitinating enzyme USP48 degrades oncogenic HMGA2 and inhibits colorectal cancer invasion and metastasis
title_full Blockade of the deubiquitinating enzyme USP48 degrades oncogenic HMGA2 and inhibits colorectal cancer invasion and metastasis
title_fullStr Blockade of the deubiquitinating enzyme USP48 degrades oncogenic HMGA2 and inhibits colorectal cancer invasion and metastasis
title_full_unstemmed Blockade of the deubiquitinating enzyme USP48 degrades oncogenic HMGA2 and inhibits colorectal cancer invasion and metastasis
title_short Blockade of the deubiquitinating enzyme USP48 degrades oncogenic HMGA2 and inhibits colorectal cancer invasion and metastasis
title_sort blockade of the deubiquitinating enzyme usp48 degrades oncogenic hmga2 and inhibits colorectal cancer invasion and metastasis
topic Colorectal cancer
Invasion and metastasis
Post-translational modification
Ubiquitination
SUMOylation
USP48
url http://www.sciencedirect.com/science/article/pii/S221138352400008X
work_keys_str_mv AT cancheng blockadeofthedeubiquitinatingenzymeusp48degradesoncogenichmga2andinhibitscolorectalcancerinvasionandmetastasis
AT hanhuiyao blockadeofthedeubiquitinatingenzymeusp48degradesoncogenichmga2andinhibitscolorectalcancerinvasionandmetastasis
AT hengli blockadeofthedeubiquitinatingenzymeusp48degradesoncogenichmga2andinhibitscolorectalcancerinvasionandmetastasis
AT jingwenliu blockadeofthedeubiquitinatingenzymeusp48degradesoncogenichmga2andinhibitscolorectalcancerinvasionandmetastasis
AT zhengyiliu blockadeofthedeubiquitinatingenzymeusp48degradesoncogenichmga2andinhibitscolorectalcancerinvasionandmetastasis
AT yangwu blockadeofthedeubiquitinatingenzymeusp48degradesoncogenichmga2andinhibitscolorectalcancerinvasionandmetastasis
AT liangzhu blockadeofthedeubiquitinatingenzymeusp48degradesoncogenichmga2andinhibitscolorectalcancerinvasionandmetastasis
AT hejiehu blockadeofthedeubiquitinatingenzymeusp48degradesoncogenichmga2andinhibitscolorectalcancerinvasionandmetastasis
AT zhengdongfang blockadeofthedeubiquitinatingenzymeusp48degradesoncogenichmga2andinhibitscolorectalcancerinvasionandmetastasis
AT liangwu blockadeofthedeubiquitinatingenzymeusp48degradesoncogenichmga2andinhibitscolorectalcancerinvasionandmetastasis